Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.99EUR
−189.68 MEUR
80.06 M
About Syndax Pharmaceuticals, Inc.
Sector
Industry
CEO
Michael A. Metzger
Website
Headquarters
Waltham
Employees (FY)
184
Founded
2005
FIGI
BBG00CF15H10
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1T3 is 18.90 EUR — it has decreased by 1.56% in the past 24 hours. Watch SYNDAX PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SYNDAX PHARMACEUTICALS INC stocks are traded under the ticker 1T3.
1T3 stock has risen by 5.59% compared to the previous week, the month change is a 4.55% fall, over the last year SYNDAX PHARMACEUTICALS INC has showed a 5.50% decrease.
We've gathered analysts' opinions on SYNDAX PHARMACEUTICALS INC future price: according to them, 1T3 price has a max estimate of 41.91 EUR and a min estimate of 21.42 EUR. Watch 1T3 chart and read a more detailed SYNDAX PHARMACEUTICALS INC stock forecast: see what analysts think of SYNDAX PHARMACEUTICALS INC and suggest that you do with its stocks.
1T3 stock is 2.13% volatile and has beta coefficient of 2.10. Track SYNDAX PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is SYNDAX PHARMACEUTICALS INC there?
Today SYNDAX PHARMACEUTICALS INC has the market capitalization of 1.59 B, it has increased by 1.99% over the last week.
Yes, you can track SYNDAX PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
SYNDAX PHARMACEUTICALS INC is going to release the next earnings report on Aug 5, 2024. Keep track of upcoming events with our Earnings Calendar.
1T3 earnings for the last quarter are −0.79 EUR per share, whereas the estimation was −0.91 EUR resulting in a 13.13% surprise. The estimated earnings for the next quarter are −0.85 EUR per share. See more details about SYNDAX PHARMACEUTICALS INC earnings.
SYNDAX PHARMACEUTICALS INC revenue for the last quarter amounts to 0 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1T3 net income for the last quarter is −67.10 M EUR, while the quarter before that showed −65.66 M EUR of net income which accounts for −2.19% change. Track more SYNDAX PHARMACEUTICALS INC financial stats to get the full picture.
No, 1T3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 15, 2024, the company has 184.00 employees. See our rating of the largest employees — is SYNDAX PHARMACEUTICALS INC on this list?
Like other stocks, 1T3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYNDAX PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYNDAX PHARMACEUTICALS INC technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYNDAX PHARMACEUTICALS INC stock shows the buy signal. See more of SYNDAX PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.